Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria (Q35637071)

9 August 2017

1 reference

title

Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria (English)

1 reference

9 August 2017

multiple drug resistance

1 reference

David R P Guay

1

1 reference

PubMed ID

14740788

9 August 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

9 August 2017

1 reference

9 August 2017

24

1 reference

9 August 2017

1

1 reference

9 August 2017

58-68

1 reference

MRSA and MRSE: is there an answer?

9 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Drug-resistant Streptococcus pneumoniae infections: clinical importance, drug treatment, and prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Glycopeptide antibiotic resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Oxazolidinone antibiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Quinupristin/dalfopristin: a therapeutic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Mechanism of action of oritavancin and related glycopeptide antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Study on the in-vitro activity of LY333328 against gram-positive cocci

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: preliminary guidelines and interpretive criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

In vitro activity of LY333328 (oritavancin) against Gram-positive aerobic cocci and synergy with ciprofloxacin against enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

In-vitro susceptibility to LY333328 of vancomycin-resistant enterococci isolated from humans and animals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Differential antimicrobial susceptibility between human and chicken isolates of vancomycin-resistant and sensitive Enterococcus faecium

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Resistance to vancomycin, LY333328, ciprofloxacin and trovafloxacin of community-acquired and nosocomial strains of Enterococcus faecalis isolated in Badajoz (Spain) with and without high-level resistance to streptomycin and gentamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Intracellular activity of vancomycin and Ly333328, a new semisynthetic glycopeptide, against methicillin-resistant Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Effect of LY333328 against vancomycin-resistant Enterococcus faecium in a rat central venous catheter-associated infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Pharmacodynamics of Oritavancin (LY333328) in a Neutropenic-Mouse Thigh Model of Staphylococcus aureus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibil

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinum

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

In vitro activities of tigecycline (GAR-936) and 12 other antimicrobial agents against 90 Eikenella corrodens clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Disk diffusion susceptibility test development for the new glycylcycline, GAR-936

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Activity of tigecycline (GAR-936), a novel glycylcycline, against Enterococci in the mouse peritonitis model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.1.58.34808

10.1592/PHCO.24.1.58.34808

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14740788